Shop ASCO / CCO Stage IV Non-Small ... without Driver Alterations

Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Published: July 2023
Print Copy Information:
  • 14 pages
  • Spiral Bound
  • 80# Aqueous Coating
  • 4.25" x 7.25"
  • Ships in 5 – 10 business days
What's Inside
Bulk and Institutional Ordering
About the Authors
Additional Information
  • Key Points  
  • Table 
    • Definitions of PD-L1 Tumor Proportion Score (TPS) level
  • Treatment Recommendations 
    • Chemotherapy
    • First-line Therapy
    • High PD-L1 Status (TPS ≥50%), and PS 0–1 and 2
    • Second-line Therapy for Patients and PS 0–1
    • One Prior Chemotherapy Regimen
    • Third-line Therapy
    • For Cytotoxic Therapy for Patients Who Have Received Three Prior Regimens and Good PS
  • Figures
    • First-Line Treatment Options for Patients with Stage IV NSCLC Without Driver Alterations
    • Second-Line Treatment Options for Patients with Stage IV NSCLC Without Driver Alterations
    • Third-Line Treatment Options for Patients with Stage IV NSCLC Without Driver Alterations
  • For purchases under 100 in quantity, we suggest placing the order directly through the website.
  • We offer group/institutional licenses for multi-user accounts (discount amount varies depending on the number of users).
  • We are proud to offer special discounts to medical schools, training programs, students and more.
  • We offer bulk purchase discounts based on number of copies and number of titles.

Contact Us for more details

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

We are the provincial agency responsible for continually improving cancer services, and the Ontario government’s cancer advisor.


Living guidelines are routinely updated guidelines that are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. These guidelines are updated on a regular schedule, based on the work of a standing panel that reviews the literature on a continuous basis.

This pocket guide is derived from recommendations in the American Society of Clinical Oncology Guideline. This resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. The practice guidelines and additional information are available at Copyright © 2023 by American Society of Clinical Oncology. All rights reserved.

You can also find this product included in this bundle!

Need help?